BioSpace1h
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
ETF Daily News11h
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby™ (acoramidis)’
Attruby will be available at a recommended dose of 712 mg, taken twice daily, at a list price of $18,759.12 for a 28-day ...
pharmaphorum11h
NICE backs AZ/Ionis' Wainzua for ATTR polyneuropathy
Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the ...
Alnylam Pharmaceuticals: Strategic Positioning and Growth Opportunities Reinforce Buy Rating Amidst Competitive ATTR-CM Market
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
Hosted on MSN19h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
BridgeBio's Attruby (Acoramidis) Approval Could Pave Way for Long-Term Profitability
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
biopharma-reporter22h
BridgeBio wins FDA approval for inherited cardiomyopathy treatment
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...